|
Myasthenia Gravis Research Highlights: AAN 2023
This 30-minute CME program highlights the latest clinical research about myasthenia gravis, a rare, autoimmune disease that targets the neuromuscular junction.
Treatment of myasthenia gravis is highly individualized and depends greatly on the myasthenia gravis subtype of each patient as well as each patient’s comorbidities. There are currently four drugs approved by the FDA, eculizumab, efgartigimod, ravulizumab, and rozanolixizumab. There are also treatments in development. Clinical tria... |
|
Leveraging the Growing Arsenal of Adjuvant Therapies for Early-Stage NSCLC
In this activity, Dr. Helena A. Yu, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, will provide insights into strategies for leveraging the growing arsenal of adjuvant therapies for early-stage non"small cell lung cancer (NSCLC), including treatment selection and adverse event management. Start the activity now!
STATEMENT OF NEED
Lung cancer is the second most commonly diagnosed cancer and the leading cause of death for men and women worldwide. In the Unite... |
|
|
Putting the Freeze on Cold Agglutinin Disease
STATEMENT OF NEED
Cold agglutinin disease (CAD) is a rare subtype of autoimmune hemolytic anemia (AIHA) in which antibodies cause hemolysis at cold temperatures, generally between 37º to 39º Fahrenheit. Approximately 1 in a million people are affected by CAD annually, with onset usually occurring between the ages of 40 and 80 years. Individuals commonly experience fatigue, dizziness, palpitations, and shortness of breath caused by the anemia; jaundice caused by degradation of hemoglobin i... |
|
|
Exploring New Treatment Advances for Acid Sphingomyelinase Deficiency in Adults
STATEMENT OF NEED
Acid sphingomyelinase deficiency (ASMD) is a rare, hereditary lysosomal storage disease with multisystemic manifestations, including splenomegaly, hepatomegaly, interstitial lung disease, dyslipidemia, bone marrow and lymph node involvement, and sometimes neurological and peripheral nerve involvement. While the most severe form of ASMD, infantile neurovisceral ASMD, results in death in early childhood, chronic forms of ASMD have more prolonged survival but are associated w... |
|
|
Current Standards and New Directions in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura
STATEMENT OF NEED
Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life-threatening thrombotic microangiopathy with a rapid onset and progression and a mortality rate of 10% to 20% with prompt treatment. Onset of aTTP is characterized by severe thrombocytopenia, microangiopathic hemolytic anemia, and a constellation of associated symptoms including hemorrhage, neurologic and renal manifestations, cardiac abnormalities, and mesenteric ischemia (Joly et al, 2017). Survivors of f... |
|
|
Exploring Novel Treatments for Rett Syndrome
STATEMENT OF NEED
Rett syndrome is a rare, debilitating neurodevelopmental disorder almost always associated with a spontaneous mutation in the methyl-CpG-binding protein 2 (MECP2) gene on the X-chromosome. Affected individuals experience loss of purposeful hand skills, abnormalities in gait, loss of spoken language, and stereotypic hand movements, with more severe manifestations including seizures, autistic features, autonomic nervous system dysfunction, breathing abnormalities, sleep dist... |
|
|
Best Practices in Nursing Management of Chemotherapy-Induced Peripheral Neuropathy
STATEMENT OF NEED
Chemotherapy-induced peripheral neuropathy (CIPN) is a complication of cancer treatment that may impair quality of life and lead to dose reductions or discontinuation of treatment. In one study, among 105 patients receiving paclitaxel for breast cancer, 36.2% needed dose reductions due to CIPN (Timmins et al, 2021). Whereas in some patients the symptoms improve with time, in others, there is progression with permanent nerve damage (Zajączkowska et al, 2019). At present, the... |
|
|
The Safety of Opioid Use in Chronic Obstructive Pulmonary Disease
This session will evaluate the safety of opioid therapy among patients with chronic obstructive pulmonary disease (COPD). The session will cover existing safety and effectiveness evidence from clinical trials, and present the latest data from observational studies. The presentation will include a discussion of the strengths and disadvantages of observational study designs along with implications for future practice.
Approximately 15.7 million Americans (6.4%) currently are diagnosed with CO... |
|
|
The HIV Journey Staying the Course Through Critical Junctions in Care
HIV is a life-long condition that is becoming increasingly complex. Clinicians must be prepared to face myriad situations over a patient’s lifespan, relating both to their HIV and to either other comorbidities or issues such as stigma or social determinants of health. In this interactive activity, you will follow a patient diagnosed as an adolescent through his lifespan with HIV to make decisions about common challenges. Dr. Onyema Ogbuagu will review rapid ART, educating adolescents, addres... |
|
|
Hot Topics in Lupus: SLE Pathophysiology
Despite the known short- and long-term adverse outcomes related to glucocorticoid use, patients with SLE are still taking moderate to high daily doses of steroids. Fortunately, 2 biologic therapies aimed at different therapeutic targets in the type I interferon pathway and with better safety profiles than glucocorticoids are currently available for use. These biologics, along with off-label immunosuppressants, can be implemented in customized ways to mitigate or eliminate the use of glucocort... |
|
|
Hot Topics in Lupus: Individualizing Steroid-Sparing Regimens
Despite the known short- and long-term adverse outcomes related to glucocorticoid use, patients with SLE are still taking moderate to high daily doses of steroids. Fortunately, 2 biologic therapies aimed at different therapeutic targets in the type I interferon pathway and with better safety profiles than glucocorticoids are currently available for use. These biologics, along with off-label immunosuppressants, can be implemented in customized ways to mitigate or eliminate the use of glucocort... |
|
|
Hot Topics in Lupus: Targeted Biologic Treatment Options
Despite the known short- and long-term adverse outcomes related to glucocorticoid use, patients with SLE are still taking moderate to high daily doses of steroids. Fortunately, 2 biologic therapies aimed at different therapeutic targets in the type I interferon pathway and with better safety profiles than glucocorticoids are currently available for use. These biologics, along with off-label immunosuppressants, can be implemented in customized ways to mitigate or eliminate the use of glucocort... |
|
|
In Case You Missed: Utilizing the Muscarinic System to Optimize Treatment Options for Schizophrenia
Schizophrenia is an incurable, neuropsychiatric disease characterized by difficulties thinking and communicating clearly as well as psychosis (ie, “positive” symptoms); difficulty functioning socially (ie, “negative” symptoms); and cognitive impairment. As many as 34% of patients with schizophrenia have treatment-resistant schizophrenia, defined as continuing symptoms despite at least 2 trials of appropriate antipsychotic treatment, and most people do not recover from it. Patients with... |
|
|
The Pharmacist’s Role in Managing Patients with Worsening Heart Failure
Pharmacists play a vital role in the management of patients with heart failure (HF). Navigate through this interactive self-directed, pharmacist-targeted activity designed to optimize your decision-making to apply the most recent clinical trial data and guidance seen in real-world HF practice, particularly in patients with worsening HF and after recent HF hospitalization. Expert perspectives and insights cover guideline-directed medical therapy (GDMT) implementation and additional adjustment t... |
|
|
28th Annual Hypertension, Diabetes & Dyslipidemia Conference
This three day intensive conference, held on June 19-21, 2024 in Charleston, South Carolina, addresses all the issues confronting clinicians who treat challenging patients with diabetes, hypertension, and dyslipidemia and how to apply this knowledge to everyday practice.
Over the past several years controversies in the appropriate target for Hemoglobin A1C, BP, and LDL-Cholesterol on outcome improvement continue to occur in Type 2 diabetes, Hypertension, and Dyslipidemia, respectively. Desp... |
|
|
Navigating the Evolving Treatment Landscape of Renal Cell Carcinoma to Ensure Equitable Access to Quality Care
Target Audience
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
Program Overview
Therapeutic options for metastatic renal cell carcinoma (RCC) have expanded over the last decade and now include targeted therapies as well as immunotherapies. However, workforce shortages, low rates of recruitment into clinical trials, racial and socioeconomic inequities, a... |
|
|
How I Treat Paroxysmal Nocturnal Hemoglobinuria (PNH)
In this point-counterpoint digital activity, two expert faculty discuss and debate treatment selection for patients with PNH through case-based scenarios. Faculty review mechanisms of action, clinical trial data, and real-world evidence supporting divergent treatment strategies for the presented cases. How do the experts make their initial treatment selections? Why might they choose a C5 inhibitor or a C3 inhibitor? How do they assess response to treatment, and what do they do when treatment r... |
|
|
Integrating PARP Inhibitors Into Treatment for Advanced Ovarian Cancer: Strategies for Improving Care and Outcomes
Target Audience
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
Program Overview
In recent years, the emergence of novel therapeutic agents has led to improved outcomes for patients with advanced and/or platinum-resistant ovarian cancer. Yet, even with improved treatment options, oncology teams in rural and underserved settings are challenged to provide ... |
|
|
Emerging Therapies, Novel Mechanisms, and New Hope in the Treatment of PAH
The treatment landscape of pulmonary arterial hypertension (PAH) is poised to change dramatically in the near future. Designed with your questions in mind, this digital FAQ index offers succinct and relevant information for all practicing pulmonology and cardiology learners. What are some of the emerging therapies for PAH, and how do they differ from current treatment options? Which emerging therapies may be disease modifying? What clinical trial evidence is there for the treatments being inve... |
|
|
Pathways for Optimal Sequencing, Rapid Initiation, and Titration of Therapy in Patients with Heart Failure
Many patients with heart failure (HF) do not receive foundational treatment although these therapies reduce morbidity and mortality risks. The initiation and optimization of guideline-directed medical therapies (GDMT) can be challenging, but clinical practice guidelines and algorithms are available to assist.
Navigate through this interactive self-directed CME activity to apply the most recent clinical trial data and guidance to patient-specific factors seen in real-world practice. Expert p... |
|
|
Making the Call in Nonadvanced Systemic Mastocytosis Optimizing Multidisciplinary Management
Series Overview
Nonadvanced systemic mastocytosis (SM) is a group of rare disorders characterized by mast cell accumulation that results in a significant and varied symptomatic burden to the patient. The most prevalent of these symptoms include gastrointestinal symptoms, dermatological symptoms, and recurrent anaphylaxis in response to a variety of triggers such as food, insect venom, and medications. In this Phone-a-Friend series, a multidisciplinary panel of faculty experts will address the... |
|
|
Contemporary Management of Patients with Systemic Lupus Erythematosus: A Case-based Approac
This modular continuing education activity provides an update on the epidemiology, monitoring, and treatment of patients with systemic lupus erythematosus (SLE). Diane Kamen, MD, and Anca Askanase, MD, examine the current research on demographic groups with an increased risk of SLE and its severe complications, including lupus nephritis (LN). They also review the application of the most current treatment goals and classification criteria to speed diagnosis and guide disease activity monitorin... |
|
|
Top 10 COVID-19 Special Population Queries
Even though the COVID-19 pandemic is slowly becoming endemic, there are still certain populations at higher risk of progressing to severe COVID-19 should they become infected with SARS-CoV-2. These include immunocompromised groups, older patients, patients with HIV, disabilities, challenges in social determinants of health, and racial or ethnic minorities. There are treatment considerations for many of these populations, including drug-drug interactions. In this self-directed activity, Drs. Gl... |
|
|
Hot Topics in Blood-based Cancer Screening: Key Information on Multi-Cancer Early Detection from 2023 Spring Oncology Meetings
Early detection of cancer is essential to reducing the significant burdens associated with it. When cancer is detected at earlier stages, treatments can be initiated sooner, resulting in improved outcomes, reduced morbidity and mortality, and better quality of life. While the implementation of current screening guidelines has resulted in an overall reduction in cancer deaths, only 25% of cancers are diagnosed using traditional screening modalities, leaving much room for improvement. Blood-base... |
|
|
Cardiovascular Considerations in COPD Management
With cardiovascular disease coexisting in up to 60% of COPD cases, optimal management of each disease is imperative to successful patient outcomes. In this Phone-a-Friend episode, Dr. MeiLan Han consults with Dr. Ty Gluckman to discuss a patient with a 5-year history of COPD and cardiovascular risk factors that may be contributing to his persistent symptoms. |
|
|
Multidisciplinary Strategies to Prevent Hospitalization in Patients with Worsening Heart Failure
Despite guideline-directed medical therapy, many patients with heart failure (HF) with reduced ejection fraction continue to experience worsening HF and hospitalizations. As such, it is incumbent upon clinicians to improve familiarity and competence with available therapies and clinical trial data that may guide patient selection to individualize and optimize therapy for patients with HF. In this interactive infographic, clinicians can access real-world strategies and expert insights to improv... |
|
|
CME Escape Room: Putting Together Clues in HIV, CVD, T2D, and CKD: Escaping Management Mishaps
Target Audience
The educational design of this activity addresses the needs of US and ex-US infectious disease and HIV specialist physicians, NPs, and PAs involved in the treatment of patients with HIV.
Program Overview
As people with HIV live longer, they can develop common comorbidities affecting aging patients, such as type 2 diabetes (T2D), cardiovascular disease (CVD), and chronic kidney disease (CKD). Further, weight gain may be seen in some patients, though the role of antiretrovir... |
|
|
Thymidine Kinase 2 Deficiency: From Diagnostic Odyssey to Timely Diagnosis and Treatment
Mary Kay Koenig, MD, a leader in the management of patients with mitochondrial diseases, delves into the complexities of managing patients with thymidine kinase 2 deficiency (TK2d). In this 1-hour activity, Dr. Koenig shares her insights in the clinical presentation of TK2d through real case studies and offers guidance on overcoming the ‘diagnostic odyssey’ experienced by many patients with mitochondrial disease. She also discusses the clinical criteria for referring patients to specialize... |
|
|
Treatment Considerations in Cutaneous Melanoma: From Early Stage to Late/Advanced Stage
Jason J. Luke, MD, discusses the impact of evolving therapies on the disease burden, survival, and treatment tolerability for patients with cutaneous melanoma. Recent clinical trial results and guideline updates for both perioperative and metastatic cutaneous melanoma are reviewed. To provide patient-centric care, Dr. Luke shares his expert insights and recommendations for individualizing treatment selection and sequencing, as well as providing supportive care and adverse event management. |
|
|
PARP Inhibition as Ovarian Cancer Maintenance Therapy: Improving Patient Outcomes as a Multidisciplinary Team
Ovarian cancer (OC) is often diagnosed at an advanced stage and has generally poor survival rates¬"even after aggressive surgical management and chemotherapy. Without maintenance therapy, approximately 70% of patients relapse within 3 years of treatment. Recent clinical trials of polyadenosine diphosphate-ribose polymerase (PARP) inhibitors have demonstrated substantial efficacy as maintenance therapy for OC patients. Additionally, clinical evidence suggests that daily monitoring of pati... |
|
|
Update in Clinical Cardiology - LIVE STREAMING or IN PERSON
The Comprehensive Clinical Cardiology Update
Evaluation • Treatment • Patient Care • Procedures • Challenging Cases
Update in Clinical Cardiology will be held on October 16 " 18, 2024. You have the option to attend either online as the course is live streamed or in person in Boston, MA.
OVERVIEW
This course provides comprehensive updates for state-of-the-art care and guidance to incorporate them into daily practice to optimize patient outcomes.
Coverage includes:
• ... |
|
|
Making the Case to Use JAK Inhibitors for Rheumatoid Arthritis"Who, What, When, and How
Target Audience
This activity has been designed to address the educational needs of rheumatology clinicians. It may also benefit other clinicians involved in the management of patients with rheumatoid arthritis (RA).
Program Overview
Join Dr Rigby and Dr Troum as they discuss the use of Janus kinase (JAK) inhibitors for the treatment of RA. In this program they will discuss the latest post-hoc analysis of the ORAL Surveillance trial, which shows which patients can safely and effectively u... |
|
|
Everything Cardiac (DVD-ROM)
This program provides a clinically applicable review of cardiovascular physiology and pathophysiology, cardiac assessment, cardiovascular pharmacology and interventions based on current guidelines for the most common cardiac disorders seen in clinical practice. Content includes a review of cardiac physiology that can be applied in daily practice, the physiological basis for cardiovascular drug therapy and the pathophysiology, diagnosis and guideline-based treatment strategies for heart failure... |
|
|
Clinical Questions in Cardiology: Using Glucagon-like Peptite-1 Receptor Agonists
The glucagon-like peptide-1 receptor agonist (GLP-1RA) class of medications has become an important option for treating patients with type 2 diabetes mellitus (T2D). Cardiovascular outcome trials also show that selected GLP-1RAs exert beneficial cardiovascular benefits in patients with and without T2D. In this activity, case studies commonly encountered in cardiology practice are utilized to prompt reflection on opportunities for reducing cardiovascular risk. Drawing on seminal research and th... |
|
|
Nurses Light the Path: Empowering Patients to Improve Breast Cancer Screening and Clinical Trial Representation
Target Audience
The primary target audience for this activity is Oncology Nursing Professionals (APRN, NP, RN).
Program Overview
For women with breast cancer and those at risk, disparities in screening and clinical-trial enrollment exist, particularly among racial and ethnic minority populations. Awareness of these disparities can ensure timely screening practices and help address patient fears and concerns regarding clinical trials that inhibit diverse representation in research. Younger... |
|
|
Recent Advances in the Treatment and Management of Endometrial Cancer
This live activity is designed for oncologists, obstetrics & gynecologists, primary care physicians, nurses and pharmacists engaged in the care of patients with endometrial cancer. This activity will represent a thorough team approach to patient care.
Further, this activity will address the following needs:
Clinicians require a review of risk factors and symptoms of endometrial cancer, as well as appropriate management of patients.
Clinicians need further education regarding new and... |
|
|
Advances in™ Beta-Thalassemia: The Evolving Therapeutic Landscape
Target Audience
This educational activity is directed toward hematologists and hematologist-oncologists, as well as pediatricians, nurses, nurse practitioners, physician assistants, and other clinicians involved in the management of patients with beta-thalassemia.
Program Overview
This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of β-thalassemia, with a forward-looking perspective on how new and novel agents might imp... |
|
|
Ethics for Occupational Therapists
Ethics for Occupational Therapists is a text-based, 3-hour online continuing education (CE/CEU) course that teaches OTs how to address ethical and moral dilemmas in practice.
Ethical and moral issues pervade our lives and healthcare professionals are constantly confronted with a variety of ethical and moral dilemmas. Decisions can have long-range effects professionally and personally, not only for the healthcare professional, but for patients, clients, healthcare entities, and society. Why ... |
|